Published on Linkedin on August 3rd, 2025
While everyone chases longevity drugs, the real fountain of youth sits in your liver
In the ever-expanding dialogue around longevity in a medical setting, we hear a lot about telomeres, senescence, mitochondrial decline, DNA repair, VO2 Max, stem cells and, unfortunately, an endless stream of pseudo-science powering rising commercial offers from clinics, to supplements, to gadgets. These themes dominate funding decks, clinic conversations, and social network threads that explore how to live longer and better. But, mostly overlooked, is one of the body’s most sophisticated and hard-working organs: the liver, our unsung hero.
If your liver is underperforming, your healthspan and your lifespan are already compromised.
The Silent Burden of Liver Disease in Aging
Liver dysfunction isn’t visible. It rarely announces its arrival. Instead, it creeps in a gradual storm masked by metabolic syndrome, fatigue, or nothing at all. Today, it’s estimated that more than one in three adults globally has some degree of non-alcoholic fatty liver disease (NAFLD), a condition now renamed MASLD (metabolic dysfunction–associated steatotic liver disease) to better reflect its metabolic roots (Younossi et al., 2016). Its progressive form, MASH (formerly NASH), is rapidly becoming a leading cause of liver transplantation.
You don’t have to be obese, diabetic, or visibly unwell to have it. The “skinny fat” phenomenon is real and prevalent. In fact, lean individuals with visceral adiposity, particularly in aging populations, are increasingly presenting with liver fibrosis without classic risk factors (Leung et al., 2021).
Liver volume decreases by 20-40% after age 65, with blood flow declining by 35% (Le Couteur & McLean, 1998). This natural deterioration accelerates disease progression, making early detection and intervention even more critical.
The Detox Myth, and the Organ That Actually Does It
In our wellness culture obsessed with “detox”, we’ve outsourced purification to green juices and charcoal smoothies. But clinically, the liver remains the body’s premier detoxifier, processing xenobiotics, hormones, alcohol, medications, and metabolic waste (Zhou et al., 2009). When it’s inflamed or overloaded, its detoxification machinery falters. Inflammation is a hallmark of MASLD!
A dysfunctional liver doesn’t just stop protecting, it becomes a problem for the whole body: Hepatocyte stress, oxidative damage, and low-grade fibrosis initiate systemic deterioration.
Chronic Inflammation, Inflammaging, and the Liver
We know that aging correlates with baseline chronic inflammation, termed “inflammaging” (Franceschi et al., 2018). What’s less often discussed is how a struggling liver becomes an active contributor to it.
In MASH, pro-inflammatory cytokines such as IL-6, TNF-α, and CRP leak into circulation and create a pro-aging internal environment. This adds to risk across every major system: cardiovascular disease, insulin resistance, immune dysfunction, and cognitive decline (Tilg & Moschen, 2010).
Fatigue, immunosenescence, poor healing, brain fog: they may not scream “liver disease,” but they often point back to it.
Aging Erodes Regeneration
Unlike many other organs, the liver is famously regenerative. But even that resilience has its limits. With age, hepatocyte turnover slows and fibrotic pathways (in particular those involving TGF-β signaling) start to outpace repair mechanisms (Schuppan et al., 2018). Liver function declines linearly at 0.038% per minute per m² per year (Le Couteur & McLean, 1998).
Left unchecked, early-stage inflammation becomes scarring, and scarring becomes cirrhosis, so often without noticeable symptoms until it’s too late. Even before reaching end-stage liver disease, fibrosis is associated with:
- Declining resilience after surgery
- Poorer chemotherapeutic tolerance
- Hormonal imbalance
- Metabolic rigidity
Simple steatosis progresses to fibrosis at 0.07 stages per year (14.3 years per stage), while MASH progresses at 0.14 stages per year (7.1 years per stage) (Singh et al., 2015). Can the famous regenerative capacity of the liver be mobilised to reverse damage? Yes, but every decade you wait to act, the price of reversal climbs higher… until it is too late.
Healthspan Starts in the Liver
When people talk about aging well, they often focus on muscle mass, cognitive sharpness, or even visible skin health. What’s often missing is what underlies it: the liver, arguably one of the most under-appreciated determinants of healthspan. Subtle liver dysfunction can silently undermine quality of life long before clinical liver disease is diagnosed, and we understand quite a lot of how this comes about:
Mitochondrial efficiency and metabolic flexibility
The liver plays a central role in energy homeostasis, regulating glucose, fatty acid oxidation, and ketone production. When liver cells are inflamed or fibrotic, mitochondrial function becomes disrupted (Sunny et al., 2011). Beta-oxidation of fatty acids declines, and there’s often an increase in intracellular lipid accumulation, leading to lipotoxicity and impaired ketone production on demand.
Healthspan consequences: Individuals with early MASH may find they experience post-meal energy crashes or have difficulty switching between fuel sources (e.g., fasting or exercising) because their liver can’t efficiently metabolize stored fat or produce ketones on demand. What looks like “just low energy” may actually be impaired metabolic flexibility due to hepatic mitochondrial dysfunction.
Hormonal balance across cortisol, estrogen, insulin, and thyroid hormones
The liver regulates hormone metabolism and clearance. For example:
- It converts inactive T4 to active T3 (thyroid),
- Breaks down excess estrogen,
- Degrades insulin and clears it from the bloodstream,
- Modifies and clears cortisol.
When liver function is compromised, these hormones can become imbalanced, even if the endocrine glands themselves are healthy (van der Deure et al., 2008).
Healthspan consequences: A woman with early-stage fibrosis may experience symptoms of estrogen dominance: mood swings, fluid retention, or fibrocystic breast changes, due not to increased hormone production but impaired hepatic clearance. Similarly, insulin resistance may be partially rooted in the liver’s inability to adequately clear or respond to this hormone.
Immune competence and vaccine response
The liver is one of the body’s largest immune organs, functioning as a filtering and regulatory hub. It hosts a rich population of Kupffer cells (liver-resident macrophages) and antigen-presenting cells. In chronic liver inflammation (like in MASH), the hepatic immune environment becomes dysregulated, promoting systemic inflammation while lowering surveillance capacity (Albillos et al., 2020).
Healthspan consequences: Older adults with fatty liver disease are found to mount weaker responses to vaccines like the influenza or COVID-19 vaccines, with reduced antibody and T-cell responses documented in clinical studies (Wang et al., 2022). This isn’t just about aging, it’s about impaired liver-mediated immune modulation.
Neurocognitive clarity and mental stability
The liver helps clear neurotoxic substances such as ammonia and bilirubin. As liver function declines, even subclinically, these compounds can accumulate in the bloodstream and subtly affect the brain. Impaired bile acid metabolism and inflammation also disturb the gut-liver-brain axis (Bajaj, 2018).
Healthspan consequences: “Brain fog” in patients with subtle liver dysfunction correlates with mild hepatic encephalopathy and disrupted neurotransmitter balance. Mood disorders like irritability or mild depression are also common in individuals with histologically confirmed liver inflammation, even in the absence of cirrhosis.
Tissue regeneration and healing post-intervention
Liver dysfunction dampens the body’s regenerative processes. The liver produces key proteins involved in coagulation and tissue repair, such as fibrinogen, prothrombin, albumin, and insulin-like growth factor-1 (IGF-1) (Russell et al., 1991). Additionally, systemic inflammation from liver disease impairs wound healing.
Healthspan consequences: Older patients with undiagnosed advanced fibrosis have significantly higher complication rates and longer recovery following elective surgeries, like hip replacements or abdominal procedures, because their ability to regenerate and clot is compromised.
These are just some measurable expressions of how even mild liver dysfunction quietly ages the body from within. If our goal is not just to live longer, but better, then liver biology must be part of the conversation. And we need cost effective, informative and easy to deploy tools to monitor liver health, the tools that the precision medicine industry has not developed. And we need the therapeutical tools to modulate liver health and target its disfunction.
.
New Therapies, Smarter Monitoring
These are exfiting times as the liver is about to receive a series of new drugs soon that will empower physicians to help you improve your liver health more effectively. Take resmetirom, Madrigal’s novel thyroid receptor agonist, which received FDA approval in March 2024 under the brand name Rezdiffra (FDA, 2024). The efficacy data are promising: reduced liver fat, improved fibrosis scores, metabolic benefits. With resmetirom’s approval, the first targeted MASH therapy, we’ve entered the precision liver medicine era. But response rates remain variable, with only 60-70% of patients showing clear benefit and some developing side effects. Beyond prevention and early detection, this is where diagnostic precision is also indispensable for:
- Responder prediction: Genomic signatures identifying those who will benefit upfront
- Dynamic monitoring: Real-time fibrosis biomarkers detecting efficacy within months, not years
- Intervention timing: Catching reversible inflammation before the fibrotic point of no return
The Case for Precision Liver Medicine in Longevity
(disclaimer: shameless promotion of (my) Ophiomics and our Precision Liver Medicine)
By 2050, MASLD prevalence will reach 41.4% globally (121.9 million Americans), with MASH cirrhosis cases increasing 91% (Le et al., 2025). Meanwhile, the population over 65, those with maximum liver vulnerability, will double. We have roughly 25 years to build precision liver medicine infrastructure before this demographic tsunami peaks.
I believe that by 2030, liver health scores based on advanced diagnostics and AI will be as routine as cholesterol checks. Liver diagnostics and personalized liver care will be embedded into our approach to longevity, just as routinely as we now screen for cardiovascular or metabolic risk. But we don’t have the right tools to do it in a cost effective, informative, objective, easy to deploy manner. This is why we are striving to build the tools to support a Precision Liver Medicine.
This is the vision Ophiomics has been working toward: integrating genomics and AI-driven diagnostics to reveal what traditional imaging or biochemistry often misses. We are developing a vision that enables us to:
- Assess individual risk from liver disease
- Early detection of diseases when they are still reversible
- Stratify patients based on likely response to intervention
- Monitor treatment effectiveness dynamically
- Personalize care across the liver disease spectrum, from steatosis to hepatocellular carcinoma (HCC)
- Integrate the full complexity of liver health into objective and actionable information
References
Albillos, A., et al. (2020). Systemic inflammation and immune dysfunction in cirrhosis: Role of the gut–liver axis. Liver Int , 40(Suppl. 1), 212–219. doi.org/10.1111/liv.14461
Bajaj, J. S. (2018). The role of the gut microbiota in liver disease. Transl Res , 196, 96–100. doi.org/10.1016/j.trsl.2017.07.005
FDA. (2024). FDA approves first treatment for patients with liver scarring due to fatty liver disease. FDA Press Release , March 14, 2024. fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
Franceschi, C., et al. (2018). Inflammaging: A new immune–metabolic viewpoint for age-related diseases. Nat Rev Immunol , 18(10), 715–728. doi.org/10.1038/s41577-018-0067-2
Le, P., et al. (2025). Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050. JAMA Netw Open , 8(1), e2454707. doi.org/10.1001/jamanetworkopen.2024.54707
Le Couteur, D. G., & McLean, A. J. (1998). The aging liver: Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet , 34(5), 359–373. doi.org/10.2165/00003088-199834050-00003
Leung, J. C., et al. (2021). Clinical features and risk stratification in lean NAFLD. Nature Reviews Endocrinology , 17(3), 159–168. doi.org/10.1038/s41574-020-00441-5
Russell, W. E., et al. (1991). IGF-I and liver regeneration. Am J Physiol , 260(5 Pt 1), G806–G812. doi.org/10.1152/ajpgi.1991.260.5.G806
Schuppan, D., et al. (2018). Liver fibrosis: Direct antifibrotic agents and targeted therapies. Nat Rev Gastroenterol Hepatol , 15(6), 329–347. doi.org/10.1038/s41575-018-0001-0
Singh, S., et al. (2015). Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol , 13(4), 643–654. doi.org/10.1016/j.cgh.2014.04.014
Sunny, N. E., et al. (2011). Progressive adaptation of hepatic ketogenesis in fatty liver disease. Cell Metab , 14(5), 646–656. doi.org/10.1016/j.cmet.2011.09.009
Tilg, H., & Moschen, A. R. (2010). Evolution of inflammation in nonalcoholic fatty liver disease. Hepatology , 52(5), 1836–1846. doi.org/10.1002/hep.24001
van der Deure, W. M., et al. (2008). The role of the liver in thyroid hormone metabolism. Clin Endocrinol , 68(4), 441–446. doi.org/10.1111/j.1365-2265.2007.03052.x
Wang, H., et al. (2022). Reduced antibody and T-cell responses to COVID-19 vaccines in patients with chronic liver diseases. J Hepatol , 77(1), 205–215. doi.org/10.1016/j.jhep.2022.02.013
Younossi, Z. M., et al. (2016). Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology , 64(1), 73–84. doi.org/10.1002/hep.28431
Zhou, S. F., et al. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev , 41(2), 89–295. doi.org/10.1080/03602530902843483